Genomic amplification of MYCN plays a dominant role in determining the biologic behavior of neuroblastoma and is strongly associated with advanced stage of the disease, rapid tumor progression, therapy resistance and overall poor prognosis [25–29]. This evidence concerns the gene MYCN and neuroblastoma.